Literature DB >> 29191917

Isolated myelosarcoma is characterized by recurrent NFE2 mutations and concurrent preleukemic clones in the bone marrow.

Vladimir Lazarevic1, Christina Orsmark-Pietras2, Henrik Lilljebjörn2, Louise Pettersson3,4, Marianne Rissler2, Anna Lübking1, Mats Ehinger4, Gunnar Juliusson1,5, Thoas Fioretos2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29191917     DOI： 10.1182/blood-2017-07-793620

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Authors:  Jonas Samuel Jutzi; Titiksha Basu; Maximilian Pellmann; Sandra Kaiser; Doris Steinemann; Mathijs A Sanders; Adil S A Hinai; Annelieke Zeilemaker; Sarolta Bojtine Kovacs; Christoph Koellerer; Jenny Ostendorp; Konrad Aumann; Wei Wang; Emmanuel Raffoux; Bruno Cassinat; Lars Bullinger; Brigitte Schlegelberger; Peter J M Valk; Heike Luise Pahl
Journal:  Blood       Date:  2019-02-12       Impact factor: 22.113

2.  In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.

Authors:  Tauangtham Anekpuritanang; Matthew M Klairmont; Joel Gradowski; Kohei Hagiwara; Nathanael G Bailey; Pranil Chandra; Yiwei Liu; Heather L Mulder; John Easton; Jinghui Zhang; Michael G Martin; Anna B Owczarczyk; Jennifer B Dunlap; Guang Fan; Richard D Press; Philipp W Raess
Journal:  Blood Adv       Date:  2021-12-14

3.  Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow.

Authors:  Nils W Engel; Jochim Reinert; Nora M Borchert; Victoria Panagiota; Razif Gabdoulline; Felicitas Thol; Michael Heuser; Walter Fiedler
Journal:  Ann Hematol       Date:  2020-10-27       Impact factor: 3.673
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.